Cellectar Biosciences, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2018. This is an annual report, not a standalone fourth-quarter report. The company is a clinical-stage biopharmaceutical developer with no product revenue, focused on its phospholipid drug conjugate platform and lead candidate CLR 131.
Financial results and liquidity
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $6.84 million | $9.47 million |
| General and administrative expense | $4.82 million | $4.14 million |
| Goodwill impairment | $1.68 million | None |
| Operating loss | $13.33 million | $13.60 million |
| Net loss | $13.24 million | $13.56 million |
| Net loss attributable to common stockholders | $15.48 million | $15.01 million |
| Basic and diluted loss per share | $5.23 | $10.70 |
| Cash used in operating activities | $11.44 million | $11.02 million |
At year-end, cash and cash equivalents were $13.26 million, plus $55,000 of restricted cash, compared with $10.01 million and $55,000, respectively, in 2017. Cash increased primarily due to approximately $15.02 million of financing proceeds, partly offset by operating cash use and $330,000 of investing cash use. Management estimated working capital of approximately $12.3 million. Current assets were $13.95 million and current liabilities $1.62 million.
Total liabilities were $1.79 million; the filing reports no material outstanding borrowing at year-end. The company had repaid its Wisconsin development loans in 2017. The company reported stockholders’ equity of $13.26 million and an accumulated deficit of $97.59 million. Profit margins are not meaningful because the company reported no product revenue and continued to incur losses.
Material changes and notable items
- R&D expense fell 28%, mainly reflecting lower general R&D costs after the manufacturing-facility shutdown and increased National Cancer Institute reimbursements offset against clinical costs. Preclinical project costs increased.
- G&A expense rose 17%, principally due to higher personnel and public-company service costs.
- The company recorded a $1.68 million noncash goodwill impairment after its year-end market capitalization fell below the carrying value of net assets.
- July 2018 financing generated approximately $15.0 million net proceeds through common and preferred stock and warrants. The offering included Series E warrants for 4.14 million shares at $4.00 per share, expiring in 2023.
- A 1-for-10 reverse stock split took effect in July 2018. Year-end common shares outstanding were 4.73 million; the filing reported 4.76 million outstanding as of February 22, 2019. Warrants, convertible preferred stock and options create potential additional dilution.
Business outlook, risks, and contingencies
CLR 131 was being studied in Phase 1 and Phase 2 trials for relapsed or refractory multiple myeloma and other hematologic malignancies. The company planned to start a Phase 1 pediatric cancer study in 2019. Other PDC programs remained preclinical or in collaborations. The company reported interim clinical results, including response and disease-marker reductions, but these were based on small patient cohorts and are not definitive evidence of safety or efficacy. Some results cited in the filing were announced after year-end.
The FDA exempted CLR 131 shipments for ongoing hematology studies from an Import Alert affecting CPDC, the company’s sole supplier, and enrollment in those studies resumed. Authorization for future shipments supporting the planned pediatric study remained unresolved, delaying its initiation. The Pierre Fabre collaboration agreement expired in January 2019, although candidate evaluation continued.
Management expected the year-end cash balance to fund budgeted operations into the first quarter of 2020. Continued operations beyond that point depend on additional financing, a strategic transaction, or other funding. The auditor’s report cited recurring losses and substantial doubt about the company’s ability to continue as a going concern; the financial statements contain no adjustments for the outcome of that uncertainty. Further risks include clinical and regulatory failure, dependence on external collaborators and manufacturing, potential dilution, and the need to secure commercial partners. No material legal proceedings were reported.
Key facts for investors to verify
- Cash burn, actual spending against budget, and the timing and terms of financing needed to extend the runway.
- Whether CPDC supply and FDA shipment authorizations support continued hematology enrollment and initiation of the pediatric study.
- Updated, adequately sized clinical-trial results for CLR 131, including safety, response durability, and survival data.
- Potential dilution from outstanding warrants, convertible preferred shares and stock options, and the effects of future capital raises.
- Progress and rights under research collaborations, including the post-expiration status of the Pierre Fabre program.